Onvatilimab (JNJ-61610588) is a human IgG1 κ-anti-Vista (T-cell-activated V-domain Ig inhibitor) monoclonal antibody with antitumor activity, potentially used for treating advanced head and neck cancers.

Curculigoside B shows antioxidative and antiosteoporotic activities, it can decrease area of bone resorption pit, osteoclastic formation and TRAP activity.

6,7-dimethoxy-N-(4-nitrophenyl)quinazoli